Loading...
XLON
CREO
Market cap57mUSD
Dec 05, Last price  
10.38GBP
1D
2.47%
1Q
-20.15%
Jan 2017
-87.25%
IPO
-87.01%
Name

Creo Medical Group PLC

Chart & Performance

D1W1MN
XLON:CREO chart
P/E
P/S
10.70
EPS
Div Yield, %
Shrs. gr., 5y
23.51%
Rev. gr., 5y
212.26%
Revenues
4m
-87.01%
802,4830534,67000013,4739,429,00025,161,00027,169,00030,800,0004,000,000
Net income
-29m
L+32.26%
-1,696,670-2,382,010-3,329,590-7,765,517-8,408,598-9,872,306-15,911,150-20,316,000-24,595,000-26,936,000-21,700,000-28,700,000
CFO
-22m
L+2.78%
-1,361,368-2,274,980-3,125,676-6,914,766-6,995,690-14,195,394-11,540,996-16,085,000-25,980,000-24,988,000-21,600,000-22,200,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Creo Medical Limited engages in the research and development of electrosurgical medical devices relating to the field of surgical endoscopy in the United Kingdom. It is developing Croma, an energy platform that powers a suite of multi-modal devices to optimize treatments for patients and physicians. The company also offers Speedboat Inject, an energy multimodality instrument for flexible endoscopy; Speedboat Slim, a flexible bipolar RF and microwave device for cutting and coagulation; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a flexible microwave ablation device; SlypSeal Flex, a flexible haemostasis device for the treatment of upper and lower GI bleeds; and SpydrBlade Flex, a flexible bipolar RF and microwave scissor device that grasps, cuts and, coagulates highlyperfused tissues. Creo Medical Limited was formerly known as MicroOncology Ltd. The company was incorporated in 2003 and is headquartered in Chepstow, the United Kingdom. Creo Medical Limited is a subsidiary of Creo Medical Group plc.
IPO date
Dec 09, 2016
Employees
284
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122018‑062017‑062016‑02
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT